iTrack™ is the only illuminated, micron-scale microcatheter designed to viscodilate Schlemm’s canal during MIGS with ABiC™. A standout feature of the iTrack™ is its illuminated tip, which allows you to continually monitor its location during canal circumnavigation.

ABiC WITH iTRACK

SCHEDULE A DEMO

Performed as a standalone procedure or as an adjunct to cataract surgery, ABiC is a new MIGS procedure that can comprehensively restore the natural outflow pathway in glaucoma patients.

Introducing a new comprenhensive MIGS

LEARN MORE

Vitreolysis. Redefining Convention.

Virtually every individual will experience the visual shadows caused by vitreous strands and opacities during their lifetime. Vitreolysis provides an effective outpatient-based treatment for floaters and overcomes many of the risks associated with traditional surgery.

LEARN MORE

SLT. Gentle. Effective Repeatable.

A highly effective approach for first-line glaucoma treatments, as adjunct therapy with drugs, and as alternative therapy when drugs or surgery fail, Selective Laser Trabeculoplasty (SLT) stimulates a natural healing response in the eye to manage intraocular pressure.

LEARN MORE

2RT® is a nanosecond laser therapy that stimulates a natural, biological healing response in the eye to treat degenerative retinal disease, including AMD.

For 30 years, Ellex has been at the forefront of ophthalmic innovation, introducing cutting-edge products and technologies for the diagnosis and treatment of eye disease.

Pioneering solutions for eye care since 1985.

For more than 30 years, Ellex has been committed to the fight against blindness. Our vision is to pioneer integrated medical technologies and solutions for the diagnosis and treatment of eye disease.

A Global Outlook.

Over the years, Ellex has evolved from a small scientific laser company to a global leader in medical technologies. Today, more than 30,000 Ellex laser and ultrasound systems are used around the world in the fight against blindness.

According to Ellex CEO, Mr. Tom Spurling: “This CE Mark has a global significance. The 2RT therapy materially changes the decision making process of patients and ophthalmologists faced with the prospect of retinal treatment with a laser. We call it a “cool” laser to emphasise the pain-free and damage-free outcomes for the patient. We expect that 2RT therapy will radically alter the risk/benefit assessment of patients by ophthalmologists.”

“Ellex is proud to begin the roll-out of this patented technology, particularly in light of strong interest from the European market.”

“The CE Mark specifically facilitates product sales in Europe, Australia, New Zealand, several SE Asian, Middle East and South American countries. Furthermore, it forms a foundation for registration of the product in Japan and China,” added Mr Spurling.

Following successful clinical studies, European ophthalmologists will now be able to use Ellex 2RT™ to treat Diabetic Macular Edema (DME), a common symptom of Diabetic Retinopathy that causes a decrease in visual acuity. Diabetic Retinopathy is a common complication of diabetes and affects more than 2.5 million people worldwide. Ellex 2RT™ is also undergoing clinical trials for the treatment of Early Age-Related Macular Degeneration (AMD), the leading cause of blindness in the developed world.

Ellex Medical Lasers Limited (ASX:ELX) is a global leader in the design and manufacture of ophthalmic laser and ultrasound systems used by ophthalmologists to diagnose and treat eye disease. With more than 16,000 systems delivered to the market, Ellex has evolved since 1985 from a manufacturing company of primarily OEM products, to direct marketing of its own branded products through subsidiaries in the United States, Japan, Germany and Australia, and a network of distribution partners in more than 100 countries. In recent years, Ellex has diversified its product range beyond lasers and ultrasound equipment to include distribution of a number of complementary third-party ophthalmic products.

ABOUT ELLEX 2RT

Over 10 years in the making, Retinal Rejuvenation Therapy (Ellex 2RT™) is a non-thermal laser therapy that stimulates a natural, biological healing response in the eye. Unlike conventional laser treatment, Ellex 2RT does not cause permanent collateral damage to the sensitive structures of the eye.

Ellex 2RT™ is performed using a novel laser device designed and manufactured by Ellex.

ABOUT DIABETIC RETINOPATHY

Diabetic Retinopathy is a common complication of diabetes. A progressive eye disease, it causes damage to the light sensitive film at the back of the eye, known as the retina. If left untreated, this can result in visual impairment and blindness. So acute is the problem that Diabetic Retinopathy is now included on the World Health Organization’s (WHO) priority list of diseases. The most common form of the disease, known as Diabetic Macular Edema (DME), occurs when fluid from this abnormal blood vessel growth leaks into the centre of the retina.